Drug intelligence / Profile preview

CC-98633

Development stage: Phase 1
Lead developer: Bristol Myers Squibb
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

CC-98633 is an autologous chimeric antigen receptor (CAR) T cell therapy that targets B-cell maturation antigen (BCMA), a protein highly expressed on malignant plasma cells in multiple myeloma. Upon administration, the engineered T cells specifically recognize and kill BCMA-expressing tumor cells. The therapy uses the NEX-T platform for CAR design and is being developed primarily for relapsed or refractory multiple myeloma. Clinical trials have evaluated its safety, tolerability, pharmacokinetics/pharmacodynamics, and efficacy in this patient population[1][2][3][4][5][7].

Other names: autologous BCMA-targeted CAR-T cells CC-98633

Targets

BCMA (B-cell maturation antigen)

Beyond the preview

Go deeper on CC-98633.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CC-98633.

Explore the full profile